Locations:
Search IconSearch
March 10, 2022/Cancer/Surgical Oncology

Sarcoma Nestled Between Esophagus, Trachea and Aortic Arch: A Case Study

Preoperative chemotherapy enables successful surgical resection

Liposarcoma biopsy under microscopy zoom in different ranges

A 45-year-old woman from Illinois had an enlarging thoracic inlet mass that had been initially identified in 2018 by a local physician and was assumed to be benign. Due to tumor growth, the patient underwent a needle biopsy in Chicago three years later, which revealed a low-grade mesenchymal process.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In early 2021, the patient had a virtual consultation with Daniel Raymond, MD, a thoracic surgeon in the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic, for a second opinion. Her only symptom was mild difficulty swallowing; however, given the size and location of the tumor, Dr. Raymond recommended a second biopsy.

The patient had an ultrasound-guided core needle biopsy in Cleveland Clinic’s Head & Neck Institute in mid-February 2021, which revealed a 7 x 7 x 10 cm myxoid liposarcoma nestled between the esophagus, trachea and aortic arch.

“Because of their rarity, sarcomas are frequently misdiagnosed on biopsy,” says Dr. Raymond. “Most pathologists aren’t experienced in diagnosing sarcomas, so it’s paramount that such cases be evaluated by an expert in soft tissue tumors.” Cleveland Clinic’s soft tissue pathology group is led by Brian Rubin, MD, PhD, Chair of the Robert J. Tomsich Pathology & Laboratory Medicine Institute and an expert in the diagnosis of sarcoma.

Based on the biopsy results, the patient underwent a multidisciplinary evaluation at Cleveland Clinic.

The patient’s initial evaluation revealed a myxoid liposarcoma nestled between the esophagus, trachea and aortic arch.

Preoperative therapy

The case was reviewed by Cleveland Clinic’s sarcoma tumor board, and the team embarked on a treatment plan that included induction chemotherapy and radiation therapy followed by surgical resection.

The patient underwent two cycles of ifosfamide concurrent with a radiation dose of 46 Gy in 23 fractions at her home healthcare facility in Chicago. Afterward, she returned to Cleveland Clinic for surgical resection. Preoperative imaging revealed a significant reduction in the mediastinal mass.

Advertisement

“The patient had a remarkable response to the induction therapy,” says Dr. Raymond. “Her mass decreased to 3 x 2 x 9 cm, which gave us the opportunity to perform a more reasonable oncologic resection.”

Multidisciplinary surgical team

The patient’s tumor was located predominantly in her neck, so a team led by Dr. Raymond and Eric Lamarre, MD, a surgeon in the Head & Neck Institute, performed a collar incision and midline sternotomy. Cardiac and vascular surgeons were available to assist, if necessary.

“We had to skeletonize the patient’s thoracic inlet structures, including the trachea, esophagus, innominate veins and great vessels,” explains Dr. Raymond. “Fortunately, we were able to do so without the need for major vascular resection and reconstruction.” The team was also able to preserve the recurrent laryngeal nerve in the tracheoesophageal groove, thereby circumventing any impairment to the patient’s voice.

The patient had an uncomplicated postoperative course and was discharged on postoperative day 3. She completed four cycles of adjuvant chemotherapy and shows no evidence of recurrent disease.

Dr. Raymond attributes this success to the team’s interdisciplinary collaboration and the patient’s response to preoperative induction chemotherapy.

“We have the advantage of being able to assemble a group of highly skilled clinicians in one room – oncologists, radiologists, pathologists and surgeons,” he says. “We’re able to solve difficult problems by sharing our expertise.”

Two takeaways

Dr. Raymond notes two important points from this case. First, sarcomas are frequently misdiagnosed. Therefore, it’s important to confer with expert pathologists who specialize in soft tissue tumors. Second, there are surgical options for resecting tumors in difficult locations. The patient in this case was told she wasn’t a candidate for tumor resection surgery prior to consulting with Dr. Raymond.

Advertisement

“We frequently see patients who have been told they are not candidates for surgery because their tumors involve different structures or cross barriers – from the abdomen into the chest or the neck into the chest,” explains Dr. Raymond. “These kinds of procedures may initially be too daunting for many surgeons – but, by working together, there are few limits to what our multidisciplinary teams can accomplish.”

Advertisement

Related Articles

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Patient with nebulizer
June 1, 2026/Cancer/Innovations

Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes

Direct delivery of viral-based vector KB707 to the lungs may boost anti-tumor response and help overcome immune checkpoint inhibitor resistance

Acupuncture in wrist
May 29, 2026/Cancer/Patient Support

Can Acupuncture Really Help with Cancer Treatment Side Effects?

Evidence-based recommendations for managing pain, nausea and other treatment reactions

Head and neck cancer illustration
May 28, 2026/Cancer

What Is the Outlook for Treatment De-Intensification Strategies for Head & Neck Cancer?

Emerging data and practice changes reduce toxicity burden of treatment

Ad